Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metyrapone in endogenous Cushing's syndrome
2014-000162-22Phase 4Completed
- Sponsor
- HRA Pharma
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of metyrapone in Cushing's syndrome, sponsored by HRA Pharma. Primary endpoint: Mean 24-hour urinary free cortisol. Started Oct 2014; status: completed.
02
Drugs
metyrapone
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on 2014-000162-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000162-22.